CG Oncology, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | $4.0M | $1.1M | $204,000 | — |
| Research and development | $116.6M | $82.1M | $45.8M | — |
| Operating expenses | — | $115.8M | $55.7M | — |
| Operating income | -$190.8M | -$114.7M | -$55.4M | — |
| Income tax expense | -$270,000 | $1,000 | $1,000 | — |
| Net income | -$161.0M | -$88.0M | -$48.6M | — |
| Balance Sheet | ||||
| Cash and equivalents | $32.5M | $257.1M | $8.3M | — |
| Current assets | $759.5M | $754.2M | $194.1M | — |
| Total assets | $791.6M | $754.8M | $199.3M | — |
| Current liabilities | $30.8M | $21.4M | $14.3M | — |
| Total liabilities | $39.0M | $21.4M | $14.5M | — |
| Stockholders' equity | $752.6M | $733.4M | -$123.1M | -$77.7M |
| Cash Flow Statement | ||||
| Cash from operations | -$132.3M | -$78.7M | -$45.7M | — |
| Depreciation and amortization | $1.4M | $32,000 | $17,000 | — |
| Stock-based compensation | $26.7M | $11.4M | $1.5M | — |
| Capital expenditure | $134,000 | $234,000 | — | — |
| Free cash flow | -$132.5M | -$78.9M | — | — |
| Impairments | $0 | — | — | — |
Shares outstanding 88.2M · Free float 89.6%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.